Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2189, Adebrelimab, and BP102 in Metastatic Colorectal Cancer
NCT07061210Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of hrs-2189 in colorectal cancer (metastatic) (mCRC), sponsored by Fudan University. Primary endpoint: Objective response rate at 1 year. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hrs-2189
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT07061210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061210.